Annual CFO
-$55.15 M
+$13.88 M+20.11%
31 December 2021
Summary:
Concert Pharmaceuticals annual cash flow from operations is currently -$55.15 million, with the most recent change of +$13.88 million (+20.11%) on 31 December 2021. During the last 3 years, it has risen by +$13.88 million (+20.11%).CNCE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$25.96 M
-$1.05 M-4.24%
30 September 2022
Summary:
Concert Pharmaceuticals quarterly cash flow from operations is currently -$25.96 million, with the most recent change of -$1.05 million (-4.24%) on 30 September 2022.CNCE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$109.66 M
-$7.32 M-7.15%
30 September 2022
Summary:
Concert Pharmaceuticals TTM cash flow from operations is currently -$109.66 million, with the most recent change of -$7.32 million (-7.15%) on 30 September 2022.CNCE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CNCE Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +20.1% | -39.3% | -144.2% |
| 5 y5 years | -14.8% | -65.8% | -122.4% |
CNCE Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -153.0% | -119.4% | -203.1% |
Concert Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$25.96 M(+4.2%) | -$109.66 M(+7.2%) |
| June 2022 | - | -$24.90 M(-23.0%) | -$102.34 M(+53.3%) |
| Mar 2022 | - | -$32.32 M(+22.1%) | -$66.76 M(+21.1%) |
| Dec 2021 | -$55.15 M(-20.1%) | -$26.48 M(+42.1%) | -$55.15 M(+22.8%) |
| Sept 2021 | - | -$18.64 M(-274.6%) | -$44.90 M(-3.5%) |
| June 2021 | - | $10.67 M(-151.5%) | -$46.55 M(-35.3%) |
| Mar 2021 | - | -$20.71 M(+27.6%) | -$71.92 M(+4.2%) |
| Dec 2020 | -$69.04 M(+41.6%) | -$16.23 M(-20.0%) | -$69.04 M(+1.7%) |
| Sept 2020 | - | -$20.29 M(+38.1%) | -$67.89 M(+7.3%) |
| June 2020 | - | -$14.69 M(-17.6%) | -$63.26 M(-3.1%) |
| Mar 2020 | - | -$17.83 M(+18.3%) | -$65.26 M(+33.8%) |
| Dec 2019 | -$48.76 M(+1.5%) | -$15.08 M(-3.7%) | -$48.76 M(-1.1%) |
| Sept 2019 | - | -$15.66 M(-6.2%) | -$49.30 M(+9.9%) |
| June 2019 | - | -$16.69 M(+1147.2%) | -$44.85 M(+21.6%) |
| Mar 2019 | - | -$1.34 M(-91.4%) | -$36.88 M(-23.2%) |
| Dec 2018 | -$48.03 M(-146.1%) | -$15.61 M(+39.3%) | -$48.03 M(+23.9%) |
| Sept 2018 | - | -$11.21 M(+28.6%) | -$38.77 M(-136.4%) |
| June 2018 | - | -$8.72 M(-30.2%) | $106.41 M(+1.6%) |
| Mar 2018 | - | -$12.48 M(+96.6%) | $104.75 M(+0.6%) |
| Dec 2017 | $104.08 M | -$6.35 M(-104.7%) | $104.08 M(+5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | $133.97 M(-1389.7%) | $98.94 M(-318.4%) |
| June 2017 | - | -$10.39 M(-21.0%) | -$45.30 M(+2.9%) |
| Mar 2017 | - | -$13.15 M(+14.4%) | -$44.02 M(-2.9%) |
| Dec 2016 | -$45.34 M(-296.6%) | -$11.50 M(+11.9%) | -$45.34 M(+38.2%) |
| Sept 2016 | - | -$10.27 M(+12.8%) | -$32.81 M(+7.8%) |
| June 2016 | - | -$9.10 M(-37.1%) | -$30.45 M(-255.1%) |
| Mar 2016 | - | -$14.47 M(-1503.5%) | $19.63 M(-14.9%) |
| Dec 2015 | $23.06 M(-177.5%) | $1.03 M(-113.0%) | $23.06 M(+64.3%) |
| Sept 2015 | - | -$7.91 M(-119.3%) | $14.04 M(-8.7%) |
| June 2015 | - | $40.97 M(-471.3%) | $15.39 M(-147.1%) |
| Mar 2015 | - | -$11.04 M(+38.1%) | -$32.70 M(+9.9%) |
| Dec 2014 | -$29.76 M(-328.6%) | -$7.99 M(+21.8%) | -$29.76 M(+8.6%) |
| Sept 2014 | - | -$6.56 M(-7.8%) | -$27.39 M(-5.2%) |
| June 2014 | - | -$7.12 M(-12.1%) | -$28.89 M(-512.1%) |
| Mar 2014 | - | -$8.10 M(+44.0%) | $7.01 M(-46.1%) |
| Dec 2013 | $13.02 M(-149.3%) | -$5.62 M(-30.3%) | $13.02 M(-30.2%) |
| Sept 2013 | - | -$8.06 M(-128.0%) | $18.64 M(-30.2%) |
| June 2013 | - | $28.79 M(-1478.2%) | $26.70 M(-1378.2%) |
| Mar 2013 | - | -$2.09 M | -$2.09 M |
| Dec 2012 | -$26.43 M(+46.1%) | - | - |
| Dec 2011 | -$18.09 M | - | - |
FAQ
- What is Concert Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Concert Pharmaceuticals?
- What is Concert Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Concert Pharmaceuticals?
- What is Concert Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Concert Pharmaceuticals?
What is Concert Pharmaceuticals annual cash flow from operations?
The current annual CFO of CNCE is -$55.15 M
What is the all time high annual CFO for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high annual cash flow from operations is $104.08 M
What is Concert Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of CNCE is -$25.96 M
What is the all time high quarterly CFO for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high quarterly cash flow from operations is $133.97 M
What is Concert Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of CNCE is -$109.66 M
What is the all time high TTM CFO for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high TTM cash flow from operations is $106.41 M